| Revision as of 21:02, 24 April 2014 editCoinmanj (talk | contribs)Extended confirmed users6,040 editsNo edit summary← Previous edit | Revision as of 10:39, 21 May 2014 edit undoLorenaaeeg (talk | contribs)6 editsNo edit summaryNext edit → | ||
| Line 51: | Line 51: | ||
| ==External links== | ==External links== | ||
| *{{RareDiseases|5686|Glycogen storage disease type 7; Muscle phosphofructokinase deficiency; Tarui disease}} | *{{RareDiseases|5686|Glycogen storage disease type 7; Muscle phosphofructokinase deficiency; Tarui disease}} | ||
| * | |||
| {{Carbohydrate metabolic pathology}} | {{Carbohydrate metabolic pathology}} | ||
Revision as of 10:39, 21 May 2014
Medical condition| Phosphofructokinase deficiency | |
|---|---|
| Specialty | Endocrinology  |
Phosphofructokinase deficiency, also known as Glycogen storage disease type VII or Tarui's disease, is metabolic disorder with autosomal recessive inheritance.
It may affect humans as well as other mammals (especially dogs). In humans it is the least common type of glycogen storage disease. It was named after the Japanese Physician, Seiichiro Tarui (1927- ).
Pathophysiology
In this condition, a deficiency of the M subunit (PFKM) of the phosphofructokinase enzyme impairs the ability of cells such as erythrocytes and rhabdomyocytes (skeletal muscle cells) to use carbohydrates (such as glucose) for energy.
The mutation impairs the ability of phosphofructokinase to phosphorylate fructose-6-phosphate prior to its cleavage into glyceraldehyde-3-phosphate which enters the energy generation phase of glycolysis, effectively limiting energy production.
Unlike most other glycogen storage diseases, it directly affects glycolysis.
Presentation
The disease presents with exercise-induced muscle cramps and weakness (sometimes rhabdomyolysis), myoglobinuria, as well as with haemolytic anaemia causing dark urine a few hours later. Hyperuricemia is common. Phosphofructokinase deficiency also presents in a rare infantile form. The infantile form causes severe myopathy and leads to death in infancy or early childhood.
Diagnosis
Other deficiency diseases with similar signs and symptoms include deficiencies of phosphoglycerate kinase, phosphoglycerate mutase, lactate dehydrogenase, beta-enolase and aldolase A.
A diagnosis can be made through a muscle biopsy that shows excess glycogen and then further tests that will show the levels of phosphofructokinase enzyme.
References
- synd/3022 at Who Named It?
- Tarui S, OKuno G, Ikura Y, Tanaka T, Suda M, Nishikawa M (1965). "Phosphofructokinase Deficiency In Skeletal Muscle. A New Type Of Glycogenosis". Biochem. Biophys. Res. Commun. 19 (4): 517–23. doi:10.1016/0006-291X(65)90156-7. PMID 14339001.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Stedman, H.; Stedman, H; Rajpurohit, Y; Henthorn, PS; Wolfe, JH; Patterson, DF; Giger, U (1996). "Molecular Basis of Canine Muscle Type Phosphofructokinase Deficiency". Journal of Biological Chemistry. 271 (33): 20070. doi:10.1074/jbc.271.33.20070. PMID 8702726.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - Nakajima H, Raben N, Hamaguchi T, Yamasaki T (2002). "Phosphofructokinase deficiency; past, present and future". Curr. Mol. Med. 2 (2): 197–212. doi:10.2174/1566524024605734. PMID 11949936.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Toscano A, Musumeci O (October 2007). "Tarui disease and distal glycogenoses: clinical and genetic update". Acta Myol. 26 (2): 105–7. PMC 2949577. PMID 18421897.
External links
- Glycogen storage disease type 7; Muscle phosphofructokinase deficiency; Tarui disease at NIH's Office of Rare Diseases
- Asociación Española de Enfermos de Glucogenosis